Porton Pharma Solutions Sustainability Profile
Porton Pharma Solutions, headquartered in China, is a leading player in the pharmaceutical and biotechnology industry, specialising in contract development and manufacturing services (CDMO). Founded in 2003, the company has established a strong presence in key operational regions, including Asia, Europe, and North America. Porton Pharma is renowned for its comprehensive range of services, including active pharmaceutical ingredient (API) production, formulation development, and clinical trial material supply. What sets Porton apart is its commitment to quality and innovation, ensuring that clients receive tailored solutions that meet stringent regulatory standards. With a robust market position, Porton Pharma Solutions has achieved significant milestones, including successful collaborations with global pharmaceutical companies, solidifying its reputation as a trusted partner in the drug development process.
DitchCarbon Score
How does Porton Pharma Solutions's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Porton Pharma Solutions's score of 42 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Porton Pharma Solutions's reported carbon emissions
In 2024, Porton Pharma Solutions reported total greenhouse gas emissions of approximately 12,305,2460 kg CO2e, comprising 18,865,220 kg CO2e from Scope 1 and 104,187,240 kg CO2e from Scope 2. This represents a significant commitment to reducing emissions, as the company has set targets to decrease absolute Scope 1 and 2 emissions by 42% by 2030, using 2023 as the base year. Additionally, Porton aims to reduce Scope 3 emissions, which include purchased goods and services, by 25% within the same timeframe. In 2023, the company’s emissions were approximately 10,969,2520 kg CO2e, with Scope 1 emissions at 19,859,890 kg CO2e and Scope 2 emissions at 89,832,630 kg CO2e. The trend shows a commitment to improving emissions intensity, with a reported GHG emissions intensity of 0.04085 CNY per unit of revenue in 2023. Porton Pharma Solutions is actively working towards its climate commitments, aligning with the Science Based Targets initiative (SBTi) to ensure that its reduction targets are consistent with the global goal of limiting temperature rise to 1.5°C. The company’s initiatives reflect a proactive approach to sustainability within the pharmaceuticals, biotechnology, and life sciences sector, based in China.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 26,761,250 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 67,599,610 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Porton Pharma Solutions's Industry?
How Carbon Intensive is Porton Pharma Solutions's Location?
Porton Pharma Solutions's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Porton Pharma Solutions has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Thermo Fisher Scientific
Sartorius
Frequently Asked Questions
Common questions about Porton Pharma Solutions's sustainability data and climate commitments